Germ-line alterations of the BRCA1 gene confer a lifetime risk of 40% for ovarian cancers and 40 -80% for breast cancers (1) . It is likely that BRCA1 acts as a tumor suppressor gene (2) . Indeed, in breast cancers linked to BRCA1, as expected for a tumor suppressor gene, allelic deletions at this locus invariably involve the wild-type allele (3, 4) . BRCA1 involvement in breast cancers does not seem to be restricted to familial cancers. Despite the absence of somatic mutation in the breast tissues, a downregulation of BRCA1 expression is associated with malignancy in human sporadic breast cancers (4 -6) .
Although its biological function is still unknown, BRCA1 may have an important role in cellular differentiation and proliferation. In transgenic mice, homozygous disruption of the Brca1 gene results in embryonic lethality (7) . The progressive changes in Brca1 expression during mouse embryogenesis (8) also imply a role for Brca1 in the differentiation process. In addition, variations of Brca1 expression are observed during postnatal mammary gland development (9, 10) . More recently, it had been shown that Cre-mediated invalidation of this gene affects final differentiation of the gland during gestation (11) . In humans, the up-regulation of BRCA1 gene expression observed during the first stages of prenatal development of the mammary gland also suggests a role for BRCA1 in the differentiation of the mammary gland (12) . Taken together, these data indicate that variations of BRCA1 expression may have some physiological consequences in human breast tissue.
Analysis of the genomic region containing this gene indicates that an another gene, NBR2, lies head to head with the BRCA1 gene (13) . Site-directed deletion mutagenesis experiments led to the identification of a bidirectional promoter region, position Ϫ258 to ϩ43 (14) , and a minimal positive regulatory region has been mapped at position Ϫ198 to Ϫ162 (15) . Structural studies have shown that a minor part of breast cancers (ϳ10%) exhibits hypermethylated sites in the region containing the putative BRCA1 promoter (16 -18) . However, a down-regulation of BRCA1 expression has been observed in most sporadic breast cancers (4 -6) , indicating that abnormal methylation of this 5Ј end region of BRCA1 does not account for the decrease in BRCA1 expression in most cases of sporadic breast cancers. In addition, in a small series (37 cases) of sporadic breast cancers, the down-regulation of BRCA1 was not correlated with DNA hypermethylation in the vicinity of the promoter region (5) .
Although transient transfection assays indicate that essential regulatory sites are not present in the upstream region (position Ϫ1528 to Ϫ202; ref 15) , it had been shown for other promoters that methylation of the surrounding sequences may repress gene expression (19) . The efficiency of the inhibition seems to be dependent on CpG density and promoter strength (19) .
We have therefore determined the methylation status of the 5Ј end of BRCA1 in a variety of cell lines and tissues, including fetal and cancer breast tissues. This analysis led to an unexpected finding, since the 5Ј end of BRCA1, which is embedded in a large CpG island, appears to be regionally methylated in all somatic tissues analyzed, suggesting that this region may participate in the regulation of BRCA1 gene expression.
Differences in DNA methylation are associated with differentiation and carcinogenesis, CpG methylation correlating with the silencing of many genes (20, 21) . Two types of mechanism could be involved in silencing genes by DNA methylation. CpG methylation can down-regulate gene expression by preventing the binding of transcription factors to their recognition sequences or through repressor molecules that bind to methylated DNA (22, 23) . The methyl-CpG binding proteins (MBD), a family of vertebrate proteins, bind to methylated DNA in any sequence context (22) ; for some members of this family it has been shown that the binding of such proteins represses gene expression at a distance (24) .
Among the DNA binding proteins potentially involved in the negative regulation of gene expression, the methyl-CpG binding protein MeCP2 seems to play an important role (25, 26) . MeCP2 is a chromosomal protein that binds specifically to methylated CpG and represses densely methylated genes in association with a histone deacetylase complex (27, 28) . Although inhibition of histone deacetylase by trichostatin A can relieve the transcriptional repression mediated by MBD (27, 28) , for some genes it has been shown that dense CpG island methylation might be a dominant factor in gene silencing (29) .
We investigated, therefore, whether methyl-CpG binding proteins such as MeCP2 might contribute to the control of BRCA1 expression.
MATERIALS AND METHODS

Preparation of tissues
Human tissues were snap frozen immediately after removal and stored in liquid nitrogen until use. Spermatozoa were purified from semen samples by Percoll gradient centrifugation (Pharmacia, Uppsala, Sweden). One milliliter of semen was loaded at the top of a 50 -90% Percoll gradient and centrifuged at 700 g for 15 min. After centrifugation, each fraction was collected by aspiration. The spermatozoa were washed in phosphate buffer 1ϫ to remove the Percoll and resuspended in an appropriate volume of phosphate-buffered saline (PBS) 1ϫ. The purity of the preparation was controlled by microscopy. Human oocytes that had failed to fertilize 3 days after in vitro insemination were collected from the In Vitro Fertilization Laboratory (Hospital E. Herriot, Lyon, France). To remove the follicular cells linked to the zonae pellucida, oocytes were treated by enzymatic digestion with hyaluronidase (150 units, type VIII hyaluronidase, Sigma, France) to discard contaminating somatic cells. Then a digestion by trypsin was performed to remove the zonae pellucida and the remaining somatic cells. Oocytes were rinsed several times in PBS 1ϫ and stored in liquid nitrogen until use. The cumulus cells were collected after hyaluronidase digestion for further studies.
Cell culture
Human breast cell lines (MCF7, BT20, and HBL 100), cervix cell line (HeLa), or kidney cell line (Bosc 23) were obtained from ATCC (Rockville, Md.) and grown in Dulbecco's modified Eagle's medium (Sigma, L'isle d'Abeau, France) supplemented with FCS 5% and 0.5 g/ml insulin for MCF7 and BT 20 cell lines. All cells were grown at 37°C in a humidified 5% CO 2 atmosphere.
PCR-based methylation assay
DNA extracted from tissue samples, cell lines, and cells treated with 5azadC were digested with a fivefold excess of RsaI or RsaI plus HpaII or CfoI and incubated overnight at 37°C in the appropriate buffer (Roche Diagnostics, Meylan, France). Control experiments were performed using the methyl-insensitive enzyme MspI. Enzymes were inactivated by heating at 65°C for 1 h and an aliquot of the reaction was used for polymerase chain reaction (PCR) amplification. The PCR amplification was performed in the following conditions: 10 mM Tris-HCl (pH 8.3), 3 mM MgCl 2 , 50 mM KCl, 0.1 mg/ml gelatin, 4% DMSO, 100 M of each of the four deoxyribonucleoside triphosphates, 0.25 M of the primers (forward: 5Ј TTG GGA GGG GGC TCG GGC AT 3Ј; reverse: 5Ј CAG AGC TGG CAG CGG ACG GT), and 0.6 units of Taq DNA polymerase (Roche Diagnostics) after 35 cycles in an Eppendorf thermocycler (1 min denaturation at 94°C, 2 min annealing at 55°C, and 3 min extension at 72°C). In each experiment, the sample digested with RsaI, which does not cleave the sequence between the two primers, was amplified to verify the efficiency of the amplification. The sequence analyzed contains 9 HpaII sites and 10 CfoI sites and PCR amplification occurs only when the sites are methylated and uncut.
5-aza-2-deoxycytidine treatments
For 5-aza-2Ј-deoxycytidine (5azadC, Sigma, France) treatments, cell lines were seeded at low density (3-4ϫ10 5 cells/ 100 mm dish) 16 h before treatment with a final concentration of 1 M 5azadC. The medium was changed 24 h after drug addition and every subsequent day. RNA and DNA were isolated after 72 h. DNAs were extracted and quantitated (Hoechst staining method) from treated cells and control cells. Different aliquots were digested by RsaI (in order to normalize the size of the DNA molecules) plus: HpaII, CfoI (methylation-sensitive enzymes), MspI (methylation-insensitive), and no enzyme. The 5Ј end of the BRCA1 gene was then amplified by PCR from these samples and the signals obtained were quantitated by densitometry. No signal was observed after MspI digestion. The extent of demethylation was evaluated by the ratio between the signal obtained after digestion by HpaII, CfoI, or both and the signal was obtained from DNAs digested with RsaI alone. The data indicated that Ͼ 90% of the DNA molecules contained unmethylated CfoI and HpaII sites after 5azadC treatment. Exon 1, which was found unmethylated in normal and tumoral tissues, was amplified as a control experiment of complete digestion with methylation-sensitive enzymes.
Transfections
pCMV-MeCP2-HA (kindly provided by Dr. A. Bird), pCMV␤gal plasmids, or pGL3-control plasmid (Promega, Lyon, France) were transfected using the calcium phosphate precipitation technique (30) . Cells were collected 48 h after transfection.
For the immunofluorescence assay, Bosc 23 cells were grown on Lab-tek Permanox (Nunc) 2-well chambered coverslips at 1 ϫ 10 5 cells per well and transfected as described previously. After 48 h, the cells were washed twice in PBS 1ϫ, fixed in paraformaldehyde 4% for 15 min at room temperature, and rinsed several times with PBS 1ϫ. Then cells were permeabilized in 0.1 M glycine-PBS 1ϫ buffer, followed by incubation in 0.5% Triton X-100-PBS 1ϫ buffer, and blocked in 0.2% gelatin-PBS 1ϫ buffer for 15 min at room temperature. The anti-tag HA monoclonal antibody (12 CA5, Roche Diagnostics) diluted 1:40 in 0.5% Triton X-100-PBS 1ϫ buffer was incubated with the cells for 1 h. The cells were rinsed several times with PBS 1ϫ and incubated for 1 h with a 1:200 dilution of the FITC-conjugated secondary antibody (goat anti-mouse IgG, Dako, France). Fluorescence was visualized with a 25ϫ or 40ϫ immersion lens on a Leica microscope. In these experiments, MeCP2 expression was consistently observed in more than 50% of the cells and ␤-galactosidase activity (30) was observed in more than 60% of the cells; five adjacent fields, at magnification 40ϫ, were counted.
pGL3 constructs, methylation, and luciferase assay
A 1757 bp fragment of the BRCA1 gene containing a part of the 5Ј CpG island and 43 bp of exon 1a was isolated from genomic DNA by PCR using primers containing KpnI site at the 5Ј end and BglII site at the 3Ј end (primer forward-KpnI: 5Ј CTG GTA CCT TGG GAG GGG GCT CGG GCA A3Ј; primer reverse-BglII: 5Ј GAA GAT CTT CCA GGA AGT CTC AGC GAG C 3Ј). The PCR products were ligated between KpnI and BglII sites into the pGL3 basic vector (Promega) and transformed into competent JM-109 Escherichia coli cells (Promega).
In vitro methylation was performed by incubating the p5Ј-BRCA1-Luc vector with one unit of either HpaII (CCGG sites), HhaI (GCGC sites), or SssI (CG sites) methylases per microgram of plasmid DNA in the conditions recommended by the manufacturer (Biolabs, Beverly, Mass.); completeness of the modification was checked with the corresponding restriction enzyme. p5Ј-BRCA1-Luc constructs were transfected into Bosc 23 cells as described previously. Transfections were optimized for 12-well plates. The cells were lysed and assayed for luciferase expression (Luciferase assay, Promega) after 48 h and the light emissions were measured in a scintillation counter (Packard, Downers Grove, Ill.). A plasmid (pGL3-control; Promega) containing a promoter and an enhancer derived from SV40 was also transfected in the same plates; values obtained for this control vector were comparable between each experiments.
DNA extraction
High molecular weight DNA was extracted from frozen pulverized tissue samples and cells by standard procedures (30) . Briefly, samples were resuspended in 10 mM Tris-0.1M EDTA buffer and digested with proteinase K (300 g/ml final concentration) in the presence of SDS. A similar method with the addition of 0.001% (V/V) ␤-2 mercaptoethanol was used to prepare decondensed DNA from spermatozoa. When DNA was extracted from a small number of cells (6 to 10 oocytes), 2 g of pGEM-T plasmid (Promega) was added as carrier. The mixture was incubated at 37°C, phenol/chloroform extracted, and DNA was ethanol-precipitated.
RNA extraction
RNA was isolated in a single step procedure by acid-guanidium-thyocyanate-phenol-chloroform extraction as described previously (31) . After extraction, total RNA was precipitated in isopropanol and resuspended in an appropriate volume of sterile water. The integrity and quantity of RNA were examined by gel electrophoresis. Total RNA was quantified by densitometry on a 1.2% agarose gel containing 0.1 g/ml ethidium bromide in comparison with serial dilutions of known amount of standard RNA (Roche Diagnostics).
Quantitative reverse transcription PCR (RT-PCR)
The RT-PCR assay was performed as described previously (32) by coamplification of 0.3 g of total RNA and a known amount of competitor RNA. Primers used were designed to amplify the cDNA fragment from exon 6 to 8 of the BRCA1 gene (C3F: 5Ј TGT GCT TTT CAG CTT GAC ACA GG 3Ј and C3R: 5Ј CGT CTT TTG AGG TTG TAT CCG CTG 3Ј). Reactions were performed in 100 l containing 10 mM Tris-HCl (pH 8.3), 3 mM MgCl 2 , 50 mM KCl, 0.1 mg/ml gelatin, 200 M of each of the 4 deoxyribonucleoside triphosphates, and 0.25 M of the C3 primers.
After initial denaturation at 92°C for 2 min, six units of Expand Reverse Transcriptase (Roche Diagnostics) were added to the reaction mixture and incubated for 35 min at 42 [de]C. Reverse transcriptase was then inactivated by heating and after cooling to 0°C, PCR amplification was accomplished by adding 0.6 units of Taq DNA polymerase (Roche Diagnostics) after 35 cycles in an Eppendorf thermocycler (1 min denaturation at 94°C, 2 min annealing at 55°C, and 3 min extension at 72°C). Aliquots were analyzed on a 2% agarose gel containing 0.1 g/ml ethidium bromide and the intensity of the bands corresponding to the wild-type BRCA1 PCR products and to the competitor PCR products was determined using Image Analyzer Software (Wayne Rasband, National Institutes of Health).
Southern blot analysis
Methylation patterns were determined by Southern blot experiments using methylation-sensitive restriction endonuclease CfoI (GCGC site) and HpaII (CCGG site) or methylation-insensitive isoschizomer MspI (CCGG site). In a typical experiment, 30 g of total DNA was cleaved with a 10-fold excess of TaqI or PstI for 10 to 12 h in the appropriate conditions (Roche Diagnostics). Two-thirds of the sample was then digested overnight by CfoI or HpaII or MspI. Restriction endonuclease products were separated by electrophoresis on a 1.2% agarose gel and transferred to Hybond N ϩ Nylon membrane (Amersham, France). After drying, the membranes were hybridized overnight at 65°C to a randomly primed 32 P-labeled probe (Random Primed DNA labeling kit, Roche Diagnostics) in the hybridization solution (0.25 M sodium phosphate, 7% SDS, 1% BSA, 50 g/ml yeast tRNA). Membranes were washed with increasing stringency (from 2 to 0.1 ϫ SSC; 0.1% SDS) at 65°C and exposed to Hyperfilm (Amersham, France) for 1 to 7 days at Ϫ70°C. Membranes could be used for rehybridization after two successive treatments with SDS 1% at 80°C for 30 min.
Gene probes
The probe used for Southern blot analysis of the CpG island of the BRCA1 gene was synthesized by PCR amplification of a 239 bp region (Ϫ1244 to Ϫ1005; ref 33). The PCR fragments were cloned into a pGEM-T vector (Promega). After digestion with the appropriate enzyme, the insert was purified by agarose gel electrophoresis, followed by electroelution. Each filter was rehybridized with the exon 1 probe encompassing exon 1a of the BRCA1 gene and the bidirectional promoter (5) in order to verify that DNA cleavage with restriction endonucleases was complete.
Bisulfite modification
The sodium bisulfite modification method, followed by the sequencing of PCR products, is used to determine the CpG methylation pattern. Sodium bisulfite converts unmethylated cytosines to uracils whereas the methylated cytosines remain unmodified. In the resultant modified DNA, uracils are replicated as thymines during PCR amplification. The sodium bisulfite reaction was carried out on 4 g of DNA (3 g of carrier DNA and 1 g of human genomic DNA). Alkalidenatured DNA was incubated in 3 M NaHSO 3 and 5 mM hydroquinone for 16 h at 50°C. Modified DNA was purified using the Wizard DNA Clean-up System (Promega) and eluted into 50 l of sterile water. Modification was completed by 0.3 M NaOH; DNA was precipitated by 0.5 M ammonium acetate (pH 4.6) and resuspended in water.
DNA was amplified using strand-specific primers designed to amplify a 258 bp region in the CpG island of the BRCA1 gene in two separate reaction mixtures. The first round of PCR amplification was accomplished in 100 l in a buffer containing 10 mM Tris-HCl (pH 8.3), 3 mM MgCl 2 , 50 mM KCl, 0.1 mg/ml gelatin, 100 M of each of the four deoxyribonucleoside triphosphates, 0.25 M of the primers (forward: 5Ј TTT TGT TTT GTG TAG GGC GGT T 3Ј; Reverse: 5Ј CCT TAA CGT CCA TTC TAA CCG T 3Ј), and 0.6 units of Taq DNA polymerase (Roche Diagnostics) after 35 cycles in an Eppendorf thermocycler (1 min denaturation at 94°C, 2 min annealing at 55°C, and 3 min extension at 72°C). An aliquot of the first amplification was reamplified with internal primers (forward: 5Ј TGA GAA TTT AAG TGG GGT GT 3Ј; reverse: 5Ј AAC CCT TCA ACC CAC CAC TAC 3Ј) in the same conditions.
PCR
Then PCR products were cloned in a pGEM-T vector (Promega) and 10 random clones were analyzed by automatic sequencing (Eurogentec, Belgium) to determine the proportion of methylated (CpG) or unmethylated (TpG) sites.
RESULTS
The 5 CpG island of BRCA1 is regionally methylated in somatic tissues
Significant variations, up to fivefold in cell lines (32) and 30-fold in sporadic breast cancers (5), in the amount of BRCA1 mRNA are not related to the methylation status of the putative promoter sequence located at the 5Ј end of the exon 1a (5). However, this unmethylated region (nt Ϫ167 to nt ϩ484) is included in a large CpG island, spanning nucleotides Ϫ2200 to ϩ500 (33 and Fig. 1E ), which suggests that hypermethylation of this CpG island could be associated with gene silencing. Analysis of the methylation status of the Ϫ1714 to Ϫ1023 region using a PCR-based methylation assay indicated that this CpG island was methylated at CfoI and HpaII sites in human somatic tissues (including normal and tumoral somatic tissues and fetal tissues, 65 samples analyzed) and cell lines (data not shown). Since this assay is qualitative rather than quantitative, methylation patterns were further determined by Southern blot experiments (representative samples are shown in Fig. 1A ).
DNAs were first digested with the methylationinsensitive restriction endonuclease PstI. Using probe 1 (position Ϫ1244 to Ϫ1005, Fig. 1C) , PstI generates two bands of 3.8 kb for the BRCA1 gene and 5 kb for the BRCA1 pseudogene (Fig. 1A, lanes  1 and 9) . When DNA extracted from the HBL 100 cell line is digested with the methylation-insensitive enzyme MspI, this probe reveals a 1008 bp band corresponding to the BRCA1 gene (Fig. 1A, lane 2) . A faint 202 bp band corresponding to the BRCA1 pseudogene was detected at the bottom of the gel. DNAs extracted from normal tissues (Fig. 1A) were digested with the methyl-sensitive enzyme HpaII that cleaves CCGG sites when the internal cytosine at CpG dinucleotide is unmethylated. Probe 1 maps a 1449 bp band (Fig. 1A, lanes 4 -7) corresponding to the methylation of 9 CCGG sites located within the 5Ј region of the BRCA1 gene (Fig. 1B and 1C) . In spermatozoa, the CCGG sites analyzed using probe 1 are unmethylated (Fig; 1A, lane 8) . DNA from the HBL 100 cell line and fetal breast tissue (Fig. 1A , lanes 10 and 11, respectively) were cleaved with the methylation-sensitive enzyme CfoI in order to map several other CpG sites. Probe 1 reveals a 924 bp band in the HBL 100 cell line and reveals a 736 bp band in tissues, indicating that the proximal CfoI sites are unmethylated in normal tissues. In spermatozoa, CpG dinucleotides located within GCGC sites are unmethylated, giving rise to a 455 bp band after hybridization with probe 1.
Taken together, these data indicate that DNAs extracted from somatic tissues and cell lines were methylated at CCGG and GCGC sites within the region spanning nucleotides Ϫ2000 to Ϫ1000 or Ϫ720 for the HBL 100 cell line, with the exception of human spermatozoa DNA, which was unmethylated at these sites (Fig. 1A) .
Analysis of the methylation pattern of the body of BRCA1 gene was carried out, as described previously (5), on several fetal and adult human tissues, cell lines, and male germ cells by Southern blot after digestion by the methylation-sensitive enzymes HpaII and CfoI (Fig. 1D) . The filters were successively hybridized with several probes corresponding to the different exons present in the 3Ј region of the BRCA1 gene. The body of the gene (from the end of exon 1b to the end of exon 24) is methylated in somatic tissues (5) and mature male germ cells, as expected for non-CpG island regions. In somatic cells, the promoter region of the gene is unmethylated, as described previously (5) . In cell lines and tissues, the 5Ј region is methylated at CCGG and GCGC sites in the various samples. On the other hand, this region is unmethylated in spermatozoa as expected for a CpG island.
The 5 CpG island of BRCA1 is unmethylated in human gametes
The gamete-specific pattern was further confirmed by scaling-down the bisulfite sequencing method in order to investigate CpG methylation from very small amounts of DNA, and experimental conditions were , and spermatozoa purified from semen sample on Percoll gradient (lane 8; 12). Southern blot experiments were performed as described in Materials and Methods. After PstI digestion (lanes 1 and 9), probe 1 reveals two bands, the 3.8 kb band corresponding to the BRCA1 gene and the 5 kb band to the BRCA1 pseudogene. When cleaved with MspI (lane 2), these two bands produce a 1008 bp band for the BRCA1 gene and a 202 bp band for the pseudogene. HpaII digestion (lanes 4 -7) generates a 1449 bp band, indicating that the 9 CCGG sites at the 5Ј end of the region analyzed are methylated. In spermatozoa (lane 8), HpaII patterns are identical to MspI patterns, indicating that these sites are unmethylated in these samples. The methylation status of GCGC sites was investigated using CfoI digestion (lanes 10 -12) and probe 1. The HBL 100 cell line (lane 10) exhibits a 924 bp band and in somatic tissues (one representative sample is shown on lane 11) a 735 bp band, indicating that the proximal CfoI sites are unmethylated in normal tissues (see Fig. 1B ). In spermatozoa, the CpG dinucleotides located within the GCGC sites are unmethylated, giving rise to a 455 bp band. B) Position of enzymatic sites in the 5Ј region of the BRCA1 gene. HpaII sites are indicated by upward strokes, CfoI sites by downward strokes. Arrows indicate the portion of DNA recognized by the probe and the size of the bands as revealed by autoradiography is indicated for the different couples of enzymes. C) Schematic representation of the promoter region of the BRCA1 gene. The BRCA1 gene spans 81 kb of genomic DNA and is located head to head with the NBR2 gene. The two genes are separated by a bidirectional promoter. The arrows point to chosen for obtaining a quantitative assay of the ratio methylated CpG vs. unmethylated CpG.
DNA extracted from purified human spermatozoa was modified by sodium bisulfite (34) . This chemical treatment converts unmethylated cytosines to uracils while methylated cytosines remain unmodified. After modification, DNA was amplified by a two step PCR method, as described in Materials and Methods. The PCR product was digested by specific restriction endonucleases to determine the global methylation status of the sample. Completeness of the modification was monitored by digestion with DdeI, which cleaves only unconverted DNA. PCR products obtained from methylated molecules exhibit a new EcoRI site at position 138, whereas unmethylated molecules exhibit a new HphI site at position 165.
The sensitivity of PCR amplification after bisulfite modification was monitored by mixing different proportions of unmethylated DNA from spermatozoa (from 25 to 100%) and methylated DNA from HBL 100 (from 0 to 75%). For each assay, an aliquot of the PCR product was cleaved with DdeI (unmodified DNA), EcoRI (methylated DNA), or HphI (unmethylated DNA), loaded on a 2% agarose gel, and visualized by ethidium bromide staining. The results indicate that the amount of PCR product cleaved by enzymatic digestion is directly related to the percentage of methylated or unmethylated DNA used in the coamplification assay ( Fig. 2A) . DNAs from somatic tissues and gametes were therefore modified using this method and PCR products were cloned and sequenced.
Within the region analyzed, Ϫ1643 to Ϫ1358, all the 24 CpG sites were unmethylated in DNA from human oocytes and spermatozoa (Fig. 2B) . As expected from the Southern blot experiments, all these CpG sites were methylated in all somatic tissues and cell lines, including the somatic cells of the corona radiata surrounding the oocytes (Fig. 2B) . The absence of DNA methylation within the CpG island in human gametes did not extend to the body of the BRCA1 gene, since control experiments indicated that two regions of the exon 11 are methylated both in somatic tissues and gametes (data not shown), suggesting that the methylation of the CpG island might play regulatory role in BRCA1 expression.
Chemically induced hypomethylation elevates BRCA1 expression
To test the potential role of DNA methylation in the control of BRCA1 expression, demethylation was induced by 5-aza-2Ј-deoxycytidine (5aza-dC) treatments. Human cell lines (three breast cell lines: BT20, MCF7, and HBL 100; one cervix cell line, HeLa; and one kidney cell line, Bosc 23) were grown for 72 h in the presence of 1 M of 5aza-dC. The PCR-based methylation assay indicated that the 5Ј end of BRCA1 was efficiently demethylated at the end of the treatment. Then the amounts of BRCA1 mRNA were determined using a competitive RT-PCR method (32) . 5aza-dC treatment invariably elevated BRCA1 expression in the cell lines analyzed by up to fivefold in BT20 cells and from 1.5 to 2.5 in the other cell lines ( Table 1 ), indicating that CpG methylation is associated with a low level of BRCA1 expression. After bisulfite modification, a DNA segment of the BRCA1 CpG island (position Ϫ1643 to Ϫ1358) was amplified (see Materials and Methods) using a two step PCR method. Ten l of PCR products obtained from DNA of spermatozoa (unmethylated) mixed with the appropriate amount (from 0 to 75%) of methylated DNA (HBL 100 cells) was digested with DdeI (lanes D), which cuts unmodified DNA; EcoRI (lanes E), which cuts at position 138 the PCR products obtained from methylated DNA; and HphI (lanes H), which cuts at position 165 the PCR products obtained from unmethylated DNA. The intensity of the corresponding bands was measured by densitometry . B) Enzymatic digestion of PCR products after bisulfite modification gives an estimation of the methylation status for only a few CpG sites (at enzymatic sites). Therefore, the methylation profile of a 258 bp region (position Ϫ1643 to Ϫ1358 from the initiation of transcription) of the CpG island of BRCA1 containing 24 CpG sites was analyzed at the nucleotide level after cloning and sequencing the PCR products obtained from various human tissues, cell lines, and male and female germ cells. Somatic cells of the corona radiata separated from the oocyte by enzymatic digestions were also analyzed as a control of the purity of the oocyte samples. Bisulfite sequences obtained from individual cloned fragments are represented as horizontal lines, with individual CpGs represented by white circles (when at least 80% of CpGs are unmethylated) or black circles (when at least 80% of the CpGs are methylated). Ten clones were analyzed for each sample. All CpG sites are methylated in somatic tissues (cumulus cells included) and human cell lines whereas the 5Ј region of the BRCA1 gene is unmethylated in both male and female human germ cells.
In vitro methylation induces a MeCP2-dependent repression of the BRCA1 promoter activity
The methylated domain of the BRCA1 CpG island is relatively far (ϳ0.7 to 1 kb, Fig. 1C, E) from the start site of the transcription. MeCP2 is able to drive a long-range repression and might down-regulated BRCA1 expression. This hypothesis was investigated using an expression vector (p5Ј-BRCA1-Luc) containing the Ϫ1714 to ϩ43 region of BRCA1 fused to the luciferase enzyme as a reporter gene.
Analysis of the 5Ј end BRCA1 sequence indicates that the CCGG sequences (HpaII sites) are located outside the minimal promoter region required for full promoter activity and only one GCGC sequence (HhaI sites) is located at the 3Ј end of this region, deletion of this latter sequence inducing only a weak inhibition of the promoter activity (15) . Therefore, we take this opportunity to investigate whether the methylation of surrounding sequences might affect BRCA1 promoter activity. p5Ј-BRCA1-Luc vector was in vitro methylated using HpaII methylase or HhaI methylase and transfected in Bosc 23 cells in the presence or absence of a vector (MeCP2-Tag-HA) encoding for MeCP2. In the absence of the MeCP2-Tag-HA vector, in vitro methylation induced only a two-to threefold drop in luciferase activity; meanwhile, in the presence of MeCP2, the in vitro methylated vectors exhibited an almost total loss of transcriptional activity (Fig. 3) . Control experiments using expression vectors containing the ␤-galactosidase gene driven by a CMV-promoter (pCMV-␤-gal plasmid) and a pGL3-control plasmid containing a SV40 promoter fused to the luciferase gene indicated that the expression of these reporters genes was not or was only minimally affected by the overexpression of the pCMV-MeCP2-HA-vector.
Therefore, cotransfection experiments in the Bosc 23 cell line indicated that partial methylation of the vector containing a part of the 5Ј end of BRCA1, which mimics the methylation pattern observed in somatic cells, induced a MeCP2-dependent repression of the transcriptional activity of this vector (Fig. 3) .
DISCUSSION
In mammalian genomes, the CpG dinucleotides are underrepresented (ϳ5 to 10% of their predicted frequency) and a high proportion (60 to 80%) is methylated. However, short regions exhibit a ratio of CpG observed vs. CpG expected of at least 0.6 and a GϩC content greater than 50%. These regions, called CpG islands, are associated with all the housekeeping genes and ϳ40% of tissue-restricted genes. Most frequently, the CpG islands are located at the 5Ј end of these genes and contain the promoter and the first exon of the associated gene (for a review, see ref 22) . Although these sequences are usually unmethylated, hypermethylation of CpG islands associated with gene silencing has been described for crucial regulator of growth during cancer progression (20) . In addition, abnormal methylation at multiple CpG-rich sequences and gene silencing are also characteristic of human and murine cell lines (35) .
In normal somatic tissues, methylated CpG islands have been found for X chromosome-inactivated genes and for imprinted genes, suggesting that the methylation of a subset of CpG islands also occurs during normal physiological process. In line with this observation, it has been shown in colon tissue that DNA methylation at CpG islands takes place during the aging process (36) .
In this study we have found that the CpG island of BRCA1 is regionally methylated in all somatic human cells and tissues analyzed, suggesting that this epigenetic modification might have some consequences on BRCA1 gene expression. Since some promoters are not or are only minimally inhibited by in vitro methylation, we have investigated the methylation sensitivity of the p-5Ј-BRCA1-Luc expression vector (containing the 5Ј end of BRCA1). In vitro methylation using M-HpaII generates a methylated site at position Ϫ167 that is not methylated in vivo, whereas the other nine sites are methylated in the cell lines and tissues analyzed. Several papers have described a bidirectional promoter in this region. For example, Thakur and Croce (15) have localized the promoter region at position Ϫ195 to Ϫ162 and a minimal positive regulatory region at position Ϫ195 to Ϫ177. This short region seems to be involved in the binding of the nuclear proteins. More recently, Suen and Gross (37) also mapped the bidirectional BRCA1 promoter in this region at position Ϫ204 to Ϫ149, and bandshift assays indicated that within this promoter the Ϫ167 to Ϫ149 region was the target of nuclear proteins. These data might suggest that the nucleotide 'C' at position Ϫ167 is not involved in the binding of potential transcription factors.
In addition, the methylation of this site (Ϫ167) does not seem to be crucial for the expression of p-5Ј-BRCA1-Luc vector since the methylation of the HhaI sites (the more proximal sites are at positions Ϫ564 and Ϫ20) has a more pronounced inhibitory effect. Furthermore, the methylation of all CpGs induces (using SssI methylase) a very strong inhibition of expression of the p-5Ј-BRCA1-luc vector, even in the absence of pCMV-MeCP2-HA vector, suggesting that the density of methylated sites is the main point of the inhibitory effect.
Although MeCP2 can bind DNA segments containing only one methylated CpG, it had been shown that the inhibitory effect of MeCP2 is strongly dependent on the density of methyl-CpGs (38) . Using p-5Ј-BRCA1-Luc vector cotransfected with a MeCP2 expression vector, in our experiments the inhibition seems dependent on the number of methylated CpGs, since the inhibition observed with HhaI methylase (16 sites) is stronger than the inhibition obtained after methylation with HpaII methylase (10 sites). These data also suggest that the inhibition of the expression of the p-5Ј-BRCA1-Luc vector by DNA methylation is not the result of the methylation of a specific site, but seems to be dependent on the methylation density.
The regional methylation of the 5Ј end BRCA1 CpG island is clearly not the consequence of a pathological process, since this pattern was observed in all normal somatic tissue samples analyzed. In contrast to the imprinted genes, this region is unmethylated in human spermatozoa and in oocytes. Furthermore, in fetal and adult tissues differential methylation between alleles was not detected. The presence, at the 5Ј end of BRCA1, of the complete long terminal repeat element pTR5, spanning nucleotides Ϫ3123 to Ϫ1273 (33), which is partially included in the BRCA1-CpG island (nt Ϫ2200 to ϩ500), might account for the partial methylation of this region. In addition, the 5Ј end of BRCA1 exhibits a complex organization since the transcription start site of BRCA1 is separated from that of the NBR2 gene by 218 bp and, therefore, its 5Ј end region in included in the intron 1 of NBR2 gene (13) . In line with this hypothesis, the promoter region of the mouse Brca1 gene, which lacks this repetitive element and complex organization (39), appears to be unmethylated in mouse somatic tissues and in the NIH 3T3 cell line (unpublished data), suggesting that insertion of the LTR element in somatic cells might have some consequences on the methylation patterns of the human BRCA1 gene.
This methylation pattern of the BRCA1 CpG island confers potential regulatory features. Our results show that BRCA1 expression is regulated at least in part by methyl-CpG binding proteins. Among this family, MeCP2 might be a good candidate since transient expression of the corresponding gene led to a methylation-dependent inhibition of BRCA1 expression. Despite the low level of MeCP2 expression (unpublished data) in the cell lines analyzed, inhibition of DNA methylation resulted in an elevated level of BRCA1 mRNA. This chemically induced hypomethylation by 5aza-dC might suggest that other members of the methyl-DNA binding proteins family are also involved in this regulation.
Transient transfection of fusion proteins have identified a MeCP2 domain that is capable of longrange repression of vectors (19, 24) . This protein, which binds to methylated CpG, forms a complex with histone deacetylase and the transcription repressor Sin3A, leading to formation of transcriptionally repressive chromatin architecture (27, 28) . MBD2 and MBD3, two other methyl-DNA binding proteins, have recently been characterized and shown to participate in other histone deacetylase complexes and in gene silencing mechanisms (40, 41) . The expression patterns of these methyl-DNA binding protein genes are not fully determined, but it has been shown in the rat that the level of MeCP2 expression is dependent on the tissues (42), MBD3 is associated with metastatic-associated protein 1, a protein that is overexpressed in several human cancers (43) , and MBD2 belongs to the MeCP1 deacetylase complex, which is also present at various levels depending on the cell type and the differentiation state (40) .
Although, genes possessing a 5Ј end methylated CpG island should represent only a very small part of the mammalian genomes, differences in the amount of methyl-DNA binding proteins between tissues or cells could represent an additional mechanism for tissue-specific gene expression.
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